Clearside shares jump as reformulated TKI drug passes mid-stage test in wet AMD
Clearside Biomedical reported positive results from a Phase 2b trial of its tyrosine kinase inhibitor in patients with wet age-related macular degeneration, bolstering its prospects of bringing a...
View ArticleZealand Pharma hit with second CRL for glucagon receptor agonist
The FDA handed down a second complete response letter to Zealand Pharma for its glucagon receptor agonist in an ultra-rare genetic disease called congenital hyperinsulinism for pediatric patients....
View ArticleCrinetics’ $500M offering; Boehringer inks deal with macrocycles biotech
Plus, news about Inhibikase, Bio-Thera, Richter, InnoCare and Scholar Rock: Crinetics prices $500M offering: The San Diego biotech upsized the offering by $100 million from $400 million. The biotech...
View ArticleNobel Prize AI winners talk about how technology could reinvent drug R&D
Artificial intelligence has its Nobel Prize moment. On Tuesday, the Nobel Prize in Physics went to a pair of longtime AI pioneers in Geoffrey Hinton and John Hopfield. Then, on Wednesday, the committee...
View ArticleClik here to view.
Illumina's pitch for new machines: You, too, can sequence DNA
Can Illumina win over labs that have never tried DNA sequencing? The company on Wednesday unveiled what it called its simplest machines yet for parsing molecular building blocks. The Miseq i100 and...
View ArticleClik here to view.
Major PBMs call for removing three FTC commissioners from insulin lawsuit
The three major PBMs being sued by the FTC have filed motions to disqualify the Democratic commissioners who would rule on the case, accusing them of bias. Alvaro Bedoya In its motion, CVS alleged the...
View ArticleCovering obesity drugs could cost Medicare $35B by 2034, budget office estimates
While Medicare doesn’t currently cover anti-obesity drugs, a new report from the Congressional Budget Office estimates that coverage could cost Medicare $35 billion from 2026 to 2034. The office...
View ArticleGSK to pay up to $2.2B to settle almost all Zantac-related court cases
GSK said Wednesday that it is paying up to $2.2 billion to resolve 93% of its US state-based liability cases related to its heartburn medicine Zantac. The UK company also agreed to a separate agreement...
View ArticleExclusive Q&A: FDA's principal deputy commissioner on taking over for Califf,...
With a new presidential administration next year, FDA Principal Deputy Commissioner Namandjé Bumpus would be in line to lead the agency if current Commissioner Robert Califf steps down after the...
View ArticleCMS looks to $2 out-of-pocket cap for some commonly used generic drugs
The Centers for Medicare and Medicaid Services on Wednesday published a list of 101 commonly used generic medicines that would cost some Medicare patients no greater than $2 per month under a proposed...
View ArticleClik here to view.
Spatial biology companies Vizgen and Ultivue merge amid ongoing lawsuits
Vizgen and Ultivue, two companies at the forefront of developing technologies that allow scientists to map the molecular makeup of cells in exquisite detail, are joining forces. The merger, announced...
View ArticleClik here to view.
Former Pfizer CEO and CFO flip on activist and say they now support company
In a late-night reversal, Pfizer’s former CEO and CFO issued a statement saying they now support the company’s existing management over activist investor Starboard Value. Frank D’Amelio “We have...
View ArticleGritstone files for bankruptcy, says it could forge a transaction as early as...
Gritstone bio filed for Chapter 11 bankruptcy on Thursday morning in a bid to keep itself afloat as it seeks a buyer or other transaction to continue running R&D of its cancer and infectious...
View ArticleClik here to view.
#CPHI24: Clients add pressure to CDMOs to source raw materials outside of...
MILAN — CDMOs are increasingly fielding inquiries from biopharma clients on how reliant they are on China for their raw materials, off the back of industry anxiety on how the Biosecure Act would play...
View ArticleExclusive: Reema Health raises $7.6M to reach people on Medicaid
A startup that helps community workers guide Medicaid members to the care they need just raised a new round of funding. People on government-run Medicaid insurance for low-income households can often...
View ArticleSuki nabs $70M Series D to arm doctors with AI tools
Suki, a startup that provides AI tools to help healthcare providers with documentation, billing and other administrative work, raised $70 million in a Series D funding round. The round was led by...
View ArticleStarboard launches first salvo in Pfizer fight, alleging ex-CEO, CFO were...
The activist investor targeting Pfizer claims that the company’s former CEO and CFO, who were previously working with the investor, were pressured to flip and side with the company. In a public letter...
View ArticleOno’s ADC deal; Leo Pharma to conduct layoffs
Plus, news about Booster Therapeutics, Century Therapeutics and Holobiome: Ono Pharmaceutical’s ADC deal: The Japanese drugmaker will pay up to $700 million to LigaChem Biosciences to develop, produce...
View ArticleAI biotechs Recursion and Exscientia first held deal talks in 2022
When Recursion Pharmaceuticals and Exscientia announced plans to merge in August, it marked the first major consolidation in the early AI-driven biotech field. The all-stock deal, touted as an alliance...
View ArticleBehind the scenes of how ex-Pfizer CEO and CFO joined activist Starboard
The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from his former CFO Frank D’Amelio. While there was no content in the email, the...
View Article